Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical Inc. reported first-quarter 2026 results that show modest growth and improved bottom-line performance while reaffirming its full-year outlook. Reported net sales were $196.7 million, up 1.6% year over year, with non-GAAP pro forma net sales of $196.4 million, up 2.7% on a constant currency basis as spine distributor transitions tapered off.
Global Spine Fixation grew 6% and Therapeutic Solutions grew 5% year over year on a constant currency basis, while Global Limb Reconstruction net sales rose 3%. GAAP net loss narrowed to $20.9 million, or $(0.52) per share, compared with a net loss of $53.1 million, or $(1.35) per share, a year earlier.
Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales, versus $11.4 million, or 6.0%, reflecting geography mix and commercial transitions. Cash, cash equivalents, and restricted cash increased to $120.9 million as of March 31, 2026, helped by financing activities, while free cash flow was negative $28.3 million. The company reaffirmed 2026 guidance for net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive full-year free cash flow excluding any potential legal settlements.
Orthofix Medical Inc. is asking shareholders to vote at its June 10, 2026 annual meeting on four items: electing ten directors, approving 2025 executive pay on an advisory basis, ratifying EY as auditor for 2026, and approving Amendment No. 5 to its stock purchase plan.
For 2025, Orthofix reported net sales of $822.3 million and a reported net loss of $(92.2) million, while non-GAAP pro forma adjusted EBITDA reached $85.9 million, or 10.6% of non-GAAP pro forma net sales. Free cash flow was $3.1 million excluding M6-related restructuring charges.
The Board highlights strong support for its pay practices, with about 98% of votes cast backing the 2025 say-on-pay proposal and at least 90% support in each of the last ten years. Most CEO and named executive officer pay is performance-based, and all directors except the CEO are independent under Nasdaq rules.
Orthofix Medical Inc. CLO Jorge Andres Cedron reported an open-market sale of 3,743 shares of common stock at $12.82 per share on April 16, 2026. According to the footnote, these shares were sold solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, Compensation and Talent Development Committee–mandated sell-to-cover requirement, leaving the executive with 59,006 shares, including 44,353 previously reported restricted stock units. The sale was made without any exercise of discretion by the reporting person.
Orthofix Medical Inc. reported preliminary first quarter 2026 net sales of approximately $196.7 million, with non-GAAP pro forma net sales of about $196.4 million, reflecting 0.4% reported growth and 3% constant currency pro forma growth versus Q1 2025. The company reaffirmed its 2026 outlook, guiding full-year net sales between $850 million and $860 million, implying about 5.5% pro forma constant currency growth at the midpoint, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow excluding potential legal settlements. Orthofix also announced a strategic realignment of its Spine leadership, eliminating the President, Global Spine Solutions role so key spine leaders now report directly to the CEO, and disclosed that President, Global Spine Max Reinhardt will depart around June 12, 2026, with severance benefits under his existing agreement.
Orthofix Medical Inc Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the class for Orthofix common stock following an internal realignment. The filing cites an internal reorganization effective January 12, 2026 and is signed on 03/27/2026.
Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, reported an open-market sale of 4,269 shares of common stock at $11.92 per share. According to the disclosure, the sale was executed solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-approved sell-to-cover arrangement.
The transaction was carried out without any exercise of discretion by Vitale. Following this tax-related sale, he holds 160,449 shares of Orthofix common stock, which includes 127,256 previously reported restricted stock units.
Orthofix Medical Inc. director Vickie L. Capps bought a total of 5,000 shares of common stock in open-market transactions. The purchases occurred on March 9–10, 2026 at prices around $12.44–$12.48 per share. Following these trades, she directly holds 27,585 shares, which include 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's stock purchase plan.
Orthofix Medical CFO Julie Andrews reported automatic share sales related to equity compensation. On March 4 and 5, 2026, she sold a total of 4,788 shares of Orthofix Medical common stock in open‑market transactions at weighted average prices of $12.9163 and $12.5508 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations in connection with the settlement of restricted stock units under a pre‑existing, mandated sell‑to‑cover arrangement approved by the Board’s Compensation and Talent Development Committee, and were executed without her discretion. After these transactions, she directly holds 88,746 shares, including 69,552 restricted stock units.
Orthofix Medical Inc. executive Lucas Vitale, listed as CP&BOO, reported selling a total of 2,312 shares of common stock in two open-market transactions on March 4 and March 5, 2026. The shares were sold at weighted average prices of $12.9163 and $12.5508 per share.
According to a footnote, these sales were made solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, committee-mandated sell-to-cover requirement, with no discretion exercised by Vitale. After these transactions, he held 164,718 shares and restricted stock units.
Orthofix Medical Inc. President & CEO Massimo Calafiore reported automatic sales of common stock tied to tax withholding on restricted stock units. On March 4, he sold 6,189 shares at a weighted average price of $12.9163, and on March 5, he sold 6,031 shares at a weighted average price of $12.5508, for a total of 12,220 shares.
The filing explains these shares were sold under a pre-existing sell-to-cover requirement to satisfy tax obligations when restricted stock units settled, and the sales were made without any exercise of discretion by him. After these transactions, he directly holds 320,136 shares of Orthofix common stock, including 221,042 restricted stock units.